Identification of New Markers in the Hypereosinophilic Syndrome

University Hospital, Lille41 enrolled

Overview

The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Hypereosinophilic Syndrome

Interventions

biologie sampleBIOLOGICAL

comparison of biomarkers between HES, HE biomarkers data and control arms

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * dated and signed informed consent * virale serology negative or negative result less than 6 months * virale serology negative for HBV or vaccinated patient * insured * virale serology negative or negative result less than 6 months * negative pregnancy test or female menopause for at least 1 year Exclusion Criteria: * subject enable adult, under guardianship or under protective measures of justice * Refusal or inability to give informed consent * The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS

Locations (1)

CHRU, Hôpital Claude Huriez

Lille, Nord, France

Outcomes

Primary Outcomes

The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia.

Time frame: one month after patient inclusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.